Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
High Risk
100%
Phase II Trial
100%
Non-muscle Invasive Bladder Cancer (NMIBC)
100%
Bacillus Calmette
100%
Atezolizumab
100%
Carcinoma in Situ
50%
Treatment-related Adverse Events
50%
Radical Cystectomy
33%
Event-free Survival
33%
Tumor-associated
16%
Disease Progression
16%
Disease Risk
16%
Complete Response
16%
Metastatic Disease
16%
Statistical Analysis
16%
Significant Risk Factors
16%
Survival Rate
16%
Bladder Cancer
16%
Pathological Complete Response
16%
Duration of Response
16%
Treatment-related Mortality
16%
Safety Analysis
16%
One Dose
16%
Standard of Care
16%
Small Sample Size
16%
Efficacy Analysis
16%
Muscle-invasive Disease
16%
Measurement Analysis
16%
In Situ Treatment
16%
Bladder Preservation
16%
95% Confidence Interval
16%
Systemic Immunotherapy
16%
90% Confidence Interval
16%
Ineligibility
16%
Medicine and Dentistry
Non Muscle Invasive Bladder Cancer
100%
Atezolizumab
100%
Adverse Event
50%
Carcinoma in Situ
50%
Immunotherapy
33%
Cystectomy
33%
Event Free Survival
33%
Disease Exacerbation
16%
Metastatic Carcinoma
16%
Survival Rate
16%
Biopsy Technique
16%
Arm
16%
Bladder
16%
Outcome Assessment
16%
Bladder Cancer
16%
Tumor
16%
Diseases
16%
Side Effect
16%
Pharmacology, Toxicology and Pharmaceutical Science
Bacilli
100%
Non Muscle Invasive Bladder Cancer
100%
Atezolizumab
100%
Adverse Event
50%
Carcinoma in Situ
50%
Immunotherapy
33%
Event Free Survival
33%
Disease Exacerbation
16%
Survival Rate
16%
Bladder Cancer
16%
Diseases
16%
Side Effect
16%